GENE ONLINE|News &
Altering the Treatment Landscape of Neurodegenerative Diseases Using Antisense Oligonucleotides (ASOs)
Advances in genetics, pharmacology, and an improved understanding of molecular mechanisms have enabled the treatment of debilitating neurodegenerative diseases with high precision. Among the various cutting-edge treatment approaches, antisense oligonucleotides (ASOs) represent a promising approach by enabling reductions or modifications in RNA and protein expression.
Approved ASO therapies for Neurodegenerative and Neuromuscular Diseases
GO Prime with only $1.49 now
LATEST
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
